Clinical trials: Amisulpride
Major Depressive Disorder (MDD)
The Effects of Dopamine on Reward Processing
The purpose of this study is to evaluate the effects of a single low dose of the D2/D3 antagonist amisulpride on reward processing.
- Trial name
- NCT01253421
- Testing
- amisulpride
- Where
- United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Healthy Participants
Influence of Dopaminergic Blockade on Stress Responses, Motivation and Emotional Reactivity in Humans.
The study aims to identify whether partial blockade of human dopamine signaling with antipsychotic drugs affects human stress responses, motivation and emotion.
- Trial name
- NCT03863691
- Testing
- Amisulpride 300 MG
- Where
- Germany
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Philipps University Marburg
Healthy
Thorough QT Study of Intravenous Amisulpride
Randomised, single-dose, crossover, placebo-controlled study to see if intravenous amisulpride has any effect on the heart rhythm, in particular the QT interval, in healthy adult volunteers.
- Trial name
- NCT02661594
- Testing
- APD421 5 mg, APD421 40 mg, Moxifloxacin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Acacia Pharma Ltd
Major Depressive Disorder (MDD), History of Childhood Sexual Abuse (CSA)
An Investigation of Early Life Stress and Depression
The purpose of this study is to investigate brain pathways within adult females (with a history of CSA that occurred between the ages of 5-14) with and without a current diagnosis of major depressive disorder (MDD).
- Trial name
- NCT01701258
- Testing
- Amisulpride
- Where
- 2 sites in United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Post Operative Nausea and Vomiting
A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea And Vomiting in the Bariatric Surgery Population
To assess the effectiveness of Amisulpride to treat Post Operative Nausea and Vomiting (PONV) and to assess the effectiveness of Amisulpride to prevent PONV following bariatric surgery.
- Trial name
- NCT06585540
- Testing
- Amisulpride IV Prevention, Amisulpride IV Treatment
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Benaroya Research Institute
Schizophrenia
Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics
This study is designed to evaluate the effects of a single dose of SEP-363856 in healthy male and female volunteers with high or low schizotype characteristics.
- Trial name
- NCT01972711
- Testing
- SEP-363856, Amisulpride
- Where
- 2 sites in United Kingdom
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bioequivalence, Schizophrenia
Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body
The experiment adopts a single center, randomized, open, single dose, two cycle, and double crossover design. The subjects were randomly divided into TR and RT groups.
- Trial name
- NCT06066112
- Testing
- Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
Normal Volunteers
Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer
The aim of the study is to investigate the negative symptoms and cognitive function after administration of antipsychotics in healthy volunteer.
- Trial name
- NCT01185418
- Testing
- risperidone, aripiprazole, haloperidol
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Negative Symptom, Schizophrenia
Study on the Gut Microbial Mechanism of Negative Symptoms of Schizophrenia
Negative symptoms are one of the five-dimensional symptoms of patients with schizophrenia, and medications are not effective in treating negative symptoms.
- Conditions
- Negative Symptom, Schizophrenia, Amisulpride, Gut Microbiomes
- Trial name
- NCT04533724
- Testing
- Amisulpride
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Major Depressive Disorder
Effects of a Single Dose of Amisulpride on Functional Brain Changes
This study is designed to investigate effects of a single dose of amisulpride on functional brain changes during reward- and motivation-related processing and at rest in healthy volunteers (HV) and in patients with Major…
- Trial name
- NCT05347199
- Testing
- Amisulpride Pill
- Where
- Germany
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Simone Grimm
Renal Disease, End Stage
PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment
The aim of the study is to understand how Amisulpride is taken up and distributed around the body and how quickly it is eliminated, when given by mouth and into a vein in adults with severe kidney disease.
- Trial name
- NCT04849650
- Testing
- Amisulpride IV, Amisulpride Oral Tablet
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Acacia Pharma Ltd
Schizophrenia, Diabetes
Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism
Patients suffering from schizophrenia have a high risk to become obese and develop diabetes. Risk of obesity is particularly high with some newer schizophrenia drugs, such as clozapine or olanzapine.
- Conditions
- Schizophrenia, Diabetes, Insulin Resistance
- Trial name
- NCT01160991
- Testing
- Glucose clamp technique, Amisulpride, Olanzapine
- Where
- Germany
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim